Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
213.20
+1.31 (+0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
39
40
Next >
National Institute on Aging Aims Building $300M Alzheimer's Research Database
April 03, 2023
The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer...
Via
Benzinga
Price Over Earnings Overview: Biogen
March 31, 2023
Via
Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
March 31, 2023
Via
Benzinga
Biogen Unusual Options Activity
March 23, 2023
Via
Benzinga
11 Analysts Have This to Say About Biogen
March 23, 2023
Via
Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
March 23, 2023
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move.
Via
InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23
March 23, 2023
Looking for longs after a clear resumption of the uptrend.
Via
Talk Markets
Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit
March 21, 2023
Via
Benzinga
Should You Buy Biogen Before a Big July Decision?
March 19, 2023
Biogen stock has dropped about 40% from its record high.
Via
The Motley Fool
Price Over Earnings Overview: Biogen
March 17, 2023
Via
Benzinga
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
March 23, 2023
The companies are focusing on a small population of ALS patients with a genetic mutation.
Via
Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
March 23, 2023
Via
Benzinga
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach
March 22, 2023
Interested in investing in iMetabolic BioPharma? Click here to get started!
Via
Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
March 21, 2023
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.
Via
InvestorPlace
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
March 20, 2023
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.
Via
Benzinga
(BIIB) - Analyzing Biogen's Short Interest
March 17, 2023
Via
Benzinga
Biogen's Debt Overview
March 15, 2023
Via
Benzinga
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
March 14, 2023
It could be a make or break year for the biotech.
Via
The Motley Fool
Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval
February 28, 2023
The FDA approved Reata's Friedreich's ataxia treatment, Skyclarys.
Via
Investor's Business Daily
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
March 16, 2023
Via
Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Via
Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
Via
Benzinga
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
March 13, 2023
Via
Benzinga
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed
March 09, 2023
The company is definitively closing the door on solanezumab.
Via
Investor's Business Daily
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
March 09, 2023
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule.
Via
InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8
March 08, 2023
Looking for a bottom in wave {v} to then look for longs.
Via
Talk Markets
Why Shares of Anavex Life Sciences Rose 12.4% in February
March 06, 2023
The company's first-quarter earnings report detailed positive news regarding its pipeline.
Via
The Motley Fool
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
March 06, 2023
Via
Benzinga
What Does Biogen's Debt Look Like?
March 02, 2023
Shares of Biogen Inc. (NASDAQ:BIIB) moved lower by 7.52% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its...
Via
Benzinga
Peering Into Biogen's Recent Short Interest
March 01, 2023
Biogen's (NASDAQ:BIIB) short percent of float has fallen 8.84% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 1.34% of all regular shares that...
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.